Creative Planning purchased a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 4,205 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of PTCT. Meeder Asset Management Inc. lifted its holdings in PTC Therapeutics by 2,347.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 1,738 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 1,667 shares in the last quarter. Exane Derivatives purchased a new stake in shares of PTC Therapeutics during the 4th quarter worth approximately $100,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of PTC Therapeutics by 15.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,596 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 474 shares in the last quarter. Tower Research Capital LLC TRC purchased a new stake in shares of PTC Therapeutics during the 3rd quarter worth approximately $130,000. Finally, Nomura Holdings Inc. purchased a new stake in shares of PTC Therapeutics during the 3rd quarter worth approximately $212,000. 99.42% of the stock is currently owned by institutional investors.
Several analysts have recently issued reports on the company. SunTrust Banks reaffirmed a “buy” rating and set a $78.00 price objective on shares of PTC Therapeutics in a report on Thursday, February 6th. TheStreet raised PTC Therapeutics from a “d” rating to a “c-” rating in a report on Tuesday, October 29th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $58.00 price objective on shares of PTC Therapeutics in a report on Thursday, December 5th. Cantor Fitzgerald upped their price objective on PTC Therapeutics from $60.00 to $81.00 and gave the stock an “overweight” rating in a report on Thursday, January 23rd. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $54.00 price objective on shares of PTC Therapeutics in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $57.00.
NASDAQ PTCT opened at $57.75 on Friday. The company has a market cap of $3.56 billion, a P/E ratio of -14.22 and a beta of 1.97. The company has a debt-to-equity ratio of 0.44, a quick ratio of 4.30 and a current ratio of 4.40. The business’s 50 day moving average price is $51.85 and its 200-day moving average price is $45.02. PTC Therapeutics, Inc. has a fifty-two week low of $29.06 and a fifty-two week high of $58.44.
In other news, CEO Stuart Walter Peltz sold 1,797 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $48.17, for a total transaction of $86,561.49. Following the transaction, the chief executive officer now owns 23,085 shares of the company’s stock, valued at approximately $1,112,004.45. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Christine Marie Utter sold 13,750 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $50.02, for a total value of $687,775.00. Following the transaction, the chief accounting officer now directly owns 5,224 shares in the company, valued at approximately $261,304.48. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,877 shares of company stock worth $1,979,457. Corporate insiders own 7.00% of the company’s stock.
PTC Therapeutics Profile
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.
See Also: Depreciation
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.